Lasmiditan
- Generic Name
- Lasmiditan
- Brand Names
- Reyvow, Rayvow
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N3O2
- CAS Number
- 439239-90-4
- Unique Ingredient Identifier
- 760I9WM792
- Background
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022.
...
- Indication
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine Headache, With or Without Aura
- Associated Therapies
- -
Litigation Surge: Drugmakers Launch Flood of Suits to Halt Generics
Law Offices of Gary Martin Hays & Associates, P.C. contact: (470) 294-1674. Law Offices of Mark E. Salomone contact: (857) 444-6468.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath